Welcome to LEAP

Press Release: Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men. View in "RECENT PUBLICATIONS".

Who Are We?

Funded by an R24 grant from the National Institutes of Health, the mission of LEAP is 3-fold:

To support scientific innovation related to the development of LA/ER antiretroviral drugs through investigator access to broad-based scientific expertise, including the pharmaceutical industry.
To develop a communications and data hub to support investigators in this field
To provide a Modeling and Simulation Core Service that helps investigators identify the most promising approaches to the development of new products.

Learn More

How Can We Help?

LEAP endeavors to serve as a central communications hub/data repository for investigators developing LA/ER treatment for HIV and TB. What information or assistance are you looking for?

Click to Ask

Need Funding?

Finding funds for research can be a challenge. The following resources are provided to help guide your efforts in seeking potential funding streams for your work. We will update this section as new opportunities are released.

Find Funds Now

Explore LEAP Resources

A major role of LEAP is to provide researchers centralized access to relevant scholarly materials, data, publications, and conference proceedings from ongoing laboratory and clinical research that catalog progress in the field.

Get Started Now

Use Our Services

Physiologically-based pharmacokinetic (PBPK) modelling and simulation of drug concentrations for LA ARV formulations can guide selection of dose, regimen, and formulation. A state-of-the-art Modeling and Simulation Core is a pivotal service offered to investigators working on preclinical and clinical development of LA/ER ARV by LEAP.

Find Out How

Main

Utility

Search form